January 10, 2022 -- Verisim Life announced it has closed an oversubscribed $15 million series A financing round. Proceeds will help Verisim scale its operations, democratize its virtual drug development engine Bioisim, fast-track its sales and marketing efforts, and continue establishing partnerships with industry and academia, the company said.
The Bioisim platform, which is driven by artificial intelligence (AI) and machine learning (ML), de-risks R&D decisions by providing meaningful insights earlier in the drug development process with unprecedented accuracy and scalability, said Verisim.
The financing was led by Morpheus Ventures. Additional new investors include Debiopharm Innovation Fund and Colorcon Ventures, with continued support from existing investors OCA Ventures, Intel Capital, Serra Ventures, and Susa Ventures.
Copyright © 2022 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
